News J&J gets restricted label for PARP drug Akeega in EU Drug is backed for BRCA+ prostate cancer patients only, a narrower group than rival Lynparza.
News Lynparza under siege in first-line prostate cancer New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.
Oncology In pursuit of a cure for cancer: An ASCO 2025 discussion wit... Dr Danny Nguyen, medical oncologist and haematologist at the City of Hope Orange County, spoke with pharmaphorum at ASCO 2025.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
